Non-alcoholic fatty liver disease and dyslipidemia: An update

详细信息    查看全文

• 作者：Niki Katsikip>ap> ; Dimitri P. Mikhailidisp>bp>p> ; p>p>MIKHAILIDIS@aol.com" class="auth_mail" title="E-mail the corresponding authorp> ; Christos S. Mantzorosp>cp>
• 关键词：Non-alcoholic fatty liver disease ; Dyslipidemia ; Statins ; Ezetimibe ; Antidiabetic drugs
• 刊名：Metabolism
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：65
• 期：8
• 页码：1109-1123
• 全文大小：708 K

文摘

Non-alcoholic fatty liver (NAFLD) is the most common liver disease worldwide, progressing from simple steatosis to necroinflammation and fibrosis (leading to non-alcoholic steatohepatitis, NASH), and in some cases to cirrhosis and hepatocellular carcinoma. Inflammation, oxidative stress and insulin resistance are involved in NAFLD development and progression. NAFLD has been associated with several cardiovascular (CV) risk factors including obesity, dyslipidemia, hyperglycemia, hypertension and smoking. NAFLD is also characterized by atherogenic dyslipidemia, postprandial lipemia and high-density lipoprotein (HDL) dysfunction. Most importantly, NAFLD patients have an increased risk for both liver and CV disease (CVD) morbidity and mortality.p><p id="sp0025">In this narrative review, the associations between NAFLD, dyslipidemia and vascular disease in NAFLD patients are discussed. NAFLD treatment is also reviewed with a focus on lipid-lowering drugs. Finally, future perspectives in terms of both NAFLD diagnostic biomarkers and therapeutic targets are considered.